Next-Generation Psychedelics

Clinical-stage psychedelics company Reunion Neuroscience (NASDAQ: REUN) is about to close on its take-private transaction with MPM BioImpact affiliates, as shareholders voted for a special resolution approving the proposed arrangement plan on July 12. Following suit, the Ontario Superior Court of...

MAPS recent Psychedelic Science 2023 conference hosted a discussion on the newly-synthesized compounds by the organization, which is advancing the legacy of the renowned chemist Alexander “Sasha” Shulgin.  The Alexander Shulgin Research Institute (ASRI)...

Lobe Sciences Ltd. (OTCQB: LOBEF), a biopharmaceutical company focused on non-hallucinatory doses of stabilized psychedelic-based compounds to treat rare diseases, has commenced its Phase 1 clinical study on proprietary psilocin analog L-130.  Conducted in Jordan under the country’s Food...

Psychedelics biotech BetterLife Pharma Inc. (OTCQB: BETRF) is fast-tracking its U.S. patent application covering the composition of matter, treatment uses and a novel production method of non-hallucinogenic LSD derivatives including the company’s 2-bromo-LSD derivative BETR-001...

Psychedelics biopharma company Cybin Inc. (NYSE: CYBN) shared its financial results for the fiscal year ended this March 31 as well as recent business highlights. Numbers show: Total cash of $12.5 (CA$16.6) million by March 31, 2023. Quarterly net loss of $10.3 million compared to $13.6 million...

Drug discovery company Mindset Pharma (OTCQB: MSSTF) received approval from the U.K. Medicines and Healthcare Products Regulatory Authority (MHRA,) and the Research Ethics Committee, to begin a Phase 2 clinical study on the safety and efficacy of its novel psilocin prodrug for the treatment of...

MDXX-class molecules biotech company PharmAla Biotech Holdings Inc. (OTCMKTS: PMBHF) has announced a non-brokered private placement of a minimum of 3.3 million units and a maximum of 16.6 million of its units at a price of $0.22 (CA$0.30) each, corresponding to aggregate gross proceeds of...

Colorado-based next-generation psychedelics biotech Mydecine Innovations Group Inc. (OTC: MYCOF) announced that, in connection with its common share subscription agreement with a third-party investor dated this past March 10, it has filed a shelf prospectus supplement to its final base shelf...

Biopharma company Psilera Inc. announced it has selected its first clinical candidate, a novel drug sharing several of psilocybin’s properties but without the hallucinogenic effects. Psilera’s work involves rethinking natural psychoactive substances into “effective and...

FSD Pharma Inc. (NASDAQ: HUGE), a biopharma company developing innovative assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, announced the first cohort of participants on its Phase 1 study assessing Lucid-21-302, or Lucid-MS, has completed...

Delix Therapeutics, a neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological conditions, received regulatory approval and is set to commence recruitment for a Phase 1 clinical trial on its non-hallucinogenic psychoplastogen lead drug candidate...

New York-based therapeutics biotech platform Terran Biosciences published a new World International Patent Organization (WIPO) application under the Patent Cooperation Treaty (PCT) to protect its novel, non-hallucinogenic psychoplastogens inspired in DMT and ibogaine with improved drug...

Numerous biopharma companies are working on enhancing first-generation or “classical” psychedelics. They're tuning down the side effects, and protecting their findings along the way. Next-gen drugs developer Mindset Pharma Inc. (OTCQB: MSSTF) has now filed two new international...

Psychedelics biotech Silo Pharma Inc. (NASDAQ: SILO) and Columbia University are developing a novel compound formulation as a prophylactic treatment for stress, anxiety and PTSD. Ketamine-based SPC-15 is currently undergoing studies on dosage and delivery methods. These, coupled with published...

Since the beginning of the new wave in medicine and public opinion, there has been a retaking of psychedelics-assisted therapy for the treatment of mental health conditions commonly known as Psychedelics Renaissance. With this, there has been an explosive number of companies working...